Poltava Medical Glass Plant JSC (PMGP, Poltava) saw its net profit decline by 15.8% in January–September 2026 compared to the same period in 2025, down to 66.05 million UAH.
According to the company’s interim report filed with the National Securities and Stock Market Commission’s disclosure system, its net sales revenue rose by 25.3% to 329.2 million UAH.
In January–September, the plant generated UAH 72.9 million in operating profit (down 14%), while gross profit increased slightly to UAH 107.5 million.
During this period, the plant manufactured 263 million ampoules and shipped 432.5 million units worth UAH 311 million.
The company generated 17.3 million UAH from the sale of oxygen and nitrogen.
As previously reported, in 2025, PZMS saw its net profit decline by 19% compared to 2024—to 105.564 million UAH—due to a 3.5% decrease in net revenue, which fell to 364.281 million UAH.
According to data from the National Securities and Stock Market Commission as of August 2026, 59.7% of the company’s authorized capital is owned by Supervisory Board Chairman Leonid Nekrasov, nearly 10% by Management Board Chairman Oleksandr Kudatsky, and another 25% is held by the pharmaceutical manufacturer PJSC “Ukrmedprom” (Kyiv), which falls under the jurisdiction of the Ministry of Health of Ukraine.
According to information on its website, the Poltava Medical Glass Plant is Ukraine’s leading manufacturer of ampoules for pharmaceuticals.
ampoule, PHARMACEUTICALS, Poltava Medical Glass Plant, PRODUCTION, PROFIT
Poltava Medical Glass Plant JSC (PMGP, Poltava) saw its net profit decline by 19% in 2025 compared to 2024—to 105.564 million UAH, and for the January–June 2026 period, by 30.5% compared to the same period in 2025, to 45.204 million UAH.
As the company reported in the NSSMC’s disclosure system, its net sales revenue in 2025 decreased by 3.52% compared to 2024—to 364.281 million UAH, while in the first half of 2026, revenue grew by 31.76% compared to the same period in 2025, reaching 231.01 million UAH.
According to the company, the main export markets outside Ukraine in 2025 were Kazakhstan, where products worth 51.503 million UAH were shipped; Georgia (3.732 million UAH); Turkey (3.233 million UAH); and Moldova (1.258 million UAH). In total, products worth 61.369 million UAH were exported during this period, which is 2.29% more than the previous year.
In the first three months of this year, the plant manufactured 89,488 million ampoules and shipped 150.923 million units worth 107.4 million UAH. Specifically, in January–March, ampoules were exported to Kazakhstan, Georgia, Turkey, Moldova, and Uzbekistan. The volume of exports increased by 32%.
The company generated 5.402 million UAH from the sale of oxygen and nitrogen.
The cost of goods sold amounted to 70.333 million UAH; the company’s revenue from core and operating activities for the first quarter of 2026 totaled 120.232 million UAH, with net profit at 21.154 million UAH.
As previously reported, in July 2025, Oleksandr Nekrasov, who owned nearly 53.7% of PZMS’s shares, gifted this stake to his relative, Leonid Oleksandrovych Nekrasov, who had previously held more than 6% of the company’s shares; following the gift, his stake exceeded 59.7% of the company’s authorized capital.
Oleksandr, Leonid, and Konstantin Oleksandrovych Nekrasov, in particular, are co-owners of the pharmaceutical manufacturer “Lubnyfarm.”
According to information on its website, the Poltava Medical Glass Plant is Ukraine’s leading manufacturer of ampoules for pharmaceuticals.
